Annual report pursuant to Section 13 and 15(d)

RFS Pharma, LLC Acquisition (Tables)

v3.3.1.900
RFS Pharma, LLC Acquisition (Tables)
12 Months Ended
Dec. 31, 2015
Business Combinations [Abstract]  
Schedule of purchase price consideration

The purchase price consideration was allocated based on the estimated fair value of the tangible and identifiable intangible assets acquired and liabilities assumed from RFS Pharma. Based upon the estimated fair values determined by the Company, the total purchase price was allocated as follows (in thousands):

       
Purchased in-process research and development   $ 184,966  
Net book value of tangible assets acquired     (182 )
Goodwill     65,195  
Deferred tax liability     (65,195 )
Total purchase price   $ 184,784